AN2 Therapeutics experienced a significant reduction in net loss and total operating expenses in the first quarter of 2025 compared to the same period in 2024. This improvement was primarily due to decreased clinical trial costs and personnel-related expenses, partially offset by increased preclinical and research study expenses.

AN2 Therapeutics reported a net loss of $7.5 million for Q4 2024, an improvement from a $16.9 million net loss in Q4 2023. The company's R&D expenses decreased significantly due to the termination of a clinical study and corporate restructuring, while its cash position remained strong at $88.6 million, anticipated to fund operations through 2027.

AN2 Therapeutics reported a net loss of $12.7 million for Q3 2024. Epetraborole-treated patients showed clinical improvements in QOL-B and MACrO2. The company plans to meet with the FDA to discuss the development path for epetraborole and is advancing its boron chemistry pipeline. They also achieved a 50% reduction in expenditures and have a cash runway through 2027.

AN2 Therapeutics reported a net loss of $14.4 million for Q2 2024, compared to a net loss of $15.8 million for the same period in 2023. The company's cash, cash equivalents, and investments totaled $104.5 million as of June 30, 2024, expected to fund operations through 2027. The company is shifting its focus to its internal boron chemistry platform and ongoing pipeline programs.